12:00 AM
 | 
Mar 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PMX-60056: Phase Ia data

Data from a dose-escalation, U.S. Phase Ia trial (56-101) in 15 healthy volunteers receiving a single 10-minute IV dose of PMX-60056 without heparin showed that hypotension was the dose-limiting effect at the...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >